Free shipping on all orders over $ 500

Exarafenib

Cat. No. M22476

All AbMole products are for research use only, cannot be used for human consumption.

Exarafenib Structure
Synonym:

KIN-2787

Size Price Availability Quantity
5mg USD 400  USD400 In stock
10mg USD 600  USD600 In stock
25mg USD 900  USD900 In stock
50mg USD 1200  USD1200 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Exarafenib (KIN-2787) is a highly selective, potent, next-generation, pan-RAF inhibitor with activity across BRAF and RAS mutant human tumor cell models. Exarafenib has anticancer activity by suppression of downstream MAPK pathway signaling. KIN-2787 in combination with binimetinib demonstrated significant combination benefit in NRAS mutant melanoma models.

Chemical Information
Molecular Weight 521.58
Formula C26H34F3N5O3
CAS Number 2639957-39-2
Solubility (25°C) DMSO 90 mg/mL
Storage 4°C, protect from light, dry, sealed
References

[1] Enrico Tiacci, et al. N Engl J Med. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia

[2] Ralf Gutzmer, et al. Lancet. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

[3] Claus Garbe, et al. Recent Results Cancer Res. Vemurafenib

[4] Reinhard Dummer, et al. Lancet Oncol. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

[5] Claus Garbe, et al. Recent Results Cancer Res. Vemurafenib

Related Raf Products
Sorafenib-d3

Sorafenib-d3 (Donafenib) is a deuterium-labeled Sorafenib, it is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.

XL-281

XL-281 (BMS-908662) is an orally active inhibitor for RAF kinase, with IC50s of 2.6, 4.5 and 6 nM, for CRAF, B-RAF, and B-RAFV600E, respectively.

B-Raf IN 2 

B-Raf IN 2 is a potent and selective BRAF inhibitor.

Brimarafenibum

Brimarafenibum (Brimarafenib) is a rapidly accelerated fibrosarcoma (Raf) kinase inhibitor, wtih antineoplastic effect.

Belvarafenib TFA

Belvarafenib TFA (HM95573 TFA) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: Exarafenib, KIN-2787 supplier, Raf, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.